Contrasting GSK (NYSE:GSK) & Arvinas (NASDAQ:ARVN)

Arvinas (NASDAQ:ARVN) and GSK (NYSE:GSK) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Earnings & Valuation

This table compares Arvinas and GSK”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60 million	2.64	-$80.80 million	($1.28)	-8.48
GSK	$43.07 billion	2.67	$7.54 billion	$3.70	15.31

GSK has higher revenue and earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 4.7% of Arvinas shares are owned by company insiders. Comparatively, 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Arvinas and GSK’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arvinas	-30.77%	-14.25%	-9.31%
GSK	17.47%	46.75%	11.53%

Analyst Ratings

This is a summary of recent ratings for Arvinas and GSK, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2	7	10	0	2.42
GSK	3	7	1	0	1.82

Arvinas presently has a consensus price target of $13.88, indicating a potential upside of 27.95%. GSK has a consensus price target of $44.13, indicating a potential downside of 22.09%. Given Arvinas’ stronger consensus rating and higher possible upside, analysts clearly believe Arvinas is more favorable than GSK.

Risk and Volatility

Arvinas has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500. Comparatively, GSK has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.

Summary

GSK beats Arvinas on 9 of the 14 factors compared between the two stocks.

About Arvinas

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.